AI assistant
Moderna, Inc. — Director's Dealing 2025
Mar 3, 2025
30610_dirs_2025-03-03_fca566fc-bfba-405b-9797-9be432836070.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Moderna, Inc. (MRNA)
CIK: 0001682852
Period of Report: 2025-02-28
Reporting Person: Mock James M (Chief Financial Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2025-02-28 | Common Stock | M | 329 | — | Acquired | 15034 | Direct |
| 2025-02-28 | Common Stock | F | 160 | $31.09 | Disposed | 14874 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2025-02-28 | Restricted Stock Units | $ | M | 329 | Disposed | Common Stock (329) | Direct | |
| 2025-03-01 | Stock Option (Right to Buy) | $30.96 | A | 63478 | Acquired | 2035-03-01 | Common Stock (63478) | Direct |
| 2025-03-01 | Restricted Stock Units | $ | A | 39606 | Acquired | Common Stock (39606) | Direct |
Footnotes
F1: Restricted stock units convert into common stock on a one-for-one basis.
F2: Represents shares withheld at the election of the Reporting Person to satisfy tax withholding obligations in connection with the vest of restricted stock units.
F3: 25% of the shares subject to this restricted stock unit award vested on February 28, 2024 with the remainder vesting in twelve (12) equal quarterly installments thereafter.
F4: 25% of this option will vest and become exercisable on March 1, 2026 with the remainder vesting in twelve (12) equal quarterly installments thereafter.
F5: 25% of the shares subject to this restricted stock unit award will vest on March 1, 2026 with the remainder vesting in twelve (12) equal quarterly installments thereafter.